Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyRegional therapyVisceral SurgeryDiseasePseudomyxoma PeritoneiSubgroupICD10C78.6MeSHSequenceChemotherapyChemo-substanceCisplatinDoxorubicinMitomycinChemo-substanceCisplatinDoxorubicinMitomycinChemo-substanceCisplatinDoxorubicinMitomycinChemo-substanceCisplatinDoxorubicinMitomycinNo. Substances12 RadiotherapySupportive therapySupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances235Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationTherapy phaseintraoperativTherapy intentionpalliativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorGovaerts KKusamura SDiseasePseudomyxoma PeritoneiPseudomyxom Peritonei nach zytoreduktiver OperationOriginDepartment of Surgical Oncology, Hospital Oost-Limburg, Genk, Belgium, Sugarbaker regimenPeritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE)Protocols in Revision 3 protocols foundProtocols under revision.HIPEC - Mitomycin 35, Pseudomyxoma Peritonei (PID2794 V1.0)HIPEC - Mitomycin 8.3 / Cisplatin 63, Pseudomyxoma Peritonei (PID2802 V1.0)Mitomycin 15 / Doxorubicin 15, Pseudomyxoma Peritonei (PID2823 V1.0)
